Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
BHP Group Half-Year Profit Surges as Copper Overtakes Iron Ore on AI-Driven Demand 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Ireland’s Data Protection Commission Launches GDPR Investigation Into X’s AI Chatbot Grok 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Anduril Industries Seeks $8 Billion Funding at $60 Billion Valuation 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
AMES, Iowa, April 30, 2018 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor conferences:
- Deutsche Bank 43rd Annual Health Care Conference on May 9 at 11:20 AM ET in Boston
- Bank of America Merrill Lynch Global Healthcare Conference 2018 on May 16 at 5:15 PM PT (8:15PM ET) in Las Vegas
A live webcast of both conference presentations will be available on the Company’s website at www.newlinkgenetics.com in the “Investors & Media” section under “Events and Presentations.”
About NewLink Genetics Corporation
NewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. For more information, please visit www.newlinkgenetics.com and follow us on Twitter @NLNKGenetics.
Investor Contact:
Lisa Miller
Director of Investor Relations
NewLink Genetics
515-598-2555
[email protected]
Media Contact:
Sharon Correia
VP, Integrated Communications
LaVoieHealthScience
617-374-8800, ext. 105
[email protected]
